DE69928932D1 - Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung - Google Patents

Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung

Info

Publication number
DE69928932D1
DE69928932D1 DE69928932T DE69928932T DE69928932D1 DE 69928932 D1 DE69928932 D1 DE 69928932D1 DE 69928932 T DE69928932 T DE 69928932T DE 69928932 T DE69928932 T DE 69928932T DE 69928932 D1 DE69928932 D1 DE 69928932D1
Authority
DE
Germany
Prior art keywords
antisense oligonucleotides
present
neoplastic cell
treatment
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928932T
Other languages
English (en)
Other versions
DE69928932T2 (de
Inventor
Paolo Renzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topigen Pharmaceuticals Inc
Original Assignee
Topigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topigen Pharmaceuticals Inc filed Critical Topigen Pharmaceuticals Inc
Publication of DE69928932D1 publication Critical patent/DE69928932D1/de
Application granted granted Critical
Publication of DE69928932T2 publication Critical patent/DE69928932T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69928932T 1998-06-17 1999-06-17 Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung Expired - Lifetime DE69928932T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002235420A CA2235420A1 (en) 1998-06-17 1998-06-17 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
CA2235420 1998-06-17
PCT/CA1999/000572 WO1999066037A2 (en) 1998-06-17 1999-06-17 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Publications (2)

Publication Number Publication Date
DE69928932D1 true DE69928932D1 (de) 2006-01-19
DE69928932T2 DE69928932T2 (de) 2006-09-07

Family

ID=4162352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928932T Expired - Lifetime DE69928932T2 (de) 1998-06-17 1999-06-17 Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung

Country Status (10)

Country Link
US (3) US6822087B1 (de)
EP (1) EP1088065B1 (de)
JP (1) JP4612188B2 (de)
AT (1) ATE312911T1 (de)
AU (1) AU758447B2 (de)
CA (1) CA2235420A1 (de)
DE (1) DE69928932T2 (de)
MX (1) MXPA00012703A (de)
NZ (1) NZ509308A (de)
WO (1) WO1999066037A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6566132B1 (en) * 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
DK1406667T3 (da) * 2001-07-06 2008-06-16 Topigen Pharmaceuticals Inc Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
AU2003268032A1 (en) * 2002-07-29 2004-02-16 Epigenesis Pharmaceuticals, Inc. Composition and methods for treatment and screening
BRPI0414886A (pt) 2003-09-29 2006-12-12 Topigen Pharma Inc composições de oligonucleotìdeo e métodos para o tratamento de doença incluindo condições inflamatórias
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
AU2005330566B2 (en) * 2004-04-29 2008-09-18 Yale University Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
ES2450929T3 (es) * 2004-10-29 2014-03-25 Topigen Pharmaceuticals Inc. Oligonucleótidos antisentido para tratar la alergia y la proliferación de las células neoplásicas
EP2316941A3 (de) * 2005-02-25 2012-03-14 Isis Pharmaceuticals, Inc. Auf IL-4R gerichtete Zusammensetzungen und deren Verwendungen
WO2007041719A2 (en) * 2005-10-03 2007-04-12 Isis Pharmaceuticals, Inc. Combination therapy using budesonide and antisense oligonucleotide targeted to il4-receptor alpha
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
CA2652539A1 (en) 2006-05-19 2007-11-29 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
AU2009246000B2 (en) 2008-05-15 2014-09-04 Topigen Pharmaceuticals Inc. Oligonucleotides for treating inflammation and neoplastic cell proliferation
US8341614B2 (en) * 2008-06-06 2012-12-25 Apple Inc. Memory management for closures
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US5874211A (en) 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
FR2734147B1 (fr) 1995-05-19 1997-10-10 Klein Jean Michel Dispositif d'osteosynthese implantable
FR2735984B1 (fr) 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997023244A1 (en) 1995-12-22 1997-07-03 Smithkline Beecham Corporation Use of antisene oligodeoxynucleotides to produce truncated proteins
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
EP1012190A4 (de) 1996-04-26 2004-04-28 Merck & Co Inc Eotaxinrezeptor aus Eosinophilen
JP2000510690A (ja) 1996-04-26 2000-08-22 インサイト・ファーマスーティカルズ・インコーポレイテッド 哺乳類混合リンパ球受容体、ケモカイン受容体（ｍｍｌｒ―ｃｃｒ）
EP1019065A4 (de) * 1997-09-17 2002-02-20 Univ East Carolina Vielzahl zielgerichteter, hybridisierender nukleinsäuren, deren synthese, zusammensetzung, formulierung, kits und anwendung
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Also Published As

Publication number Publication date
JP2002518007A (ja) 2002-06-25
AU758447B2 (en) 2003-03-20
WO1999066037A3 (en) 2000-04-20
JP4612188B2 (ja) 2011-01-12
EP1088065A2 (de) 2001-04-04
NZ509308A (en) 2003-05-30
MXPA00012703A (es) 2003-07-14
US6822087B1 (en) 2004-11-23
CA2235420A1 (en) 1999-12-17
ATE312911T1 (de) 2005-12-15
US20050282762A1 (en) 2005-12-22
WO1999066037A2 (en) 1999-12-23
US7629324B2 (en) 2009-12-08
AU4493299A (en) 2000-01-05
US20100286239A1 (en) 2010-11-11
DE69928932T2 (de) 2006-09-07
EP1088065B1 (de) 2005-12-14

Similar Documents

Publication Publication Date Title
DE69928932D1 (de) Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE60103052D1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE369844T1 (de) Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
Brzoska et al. Molecular basis of the α‐MSH/IL‐1 antagonism
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE60307237D1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
AU2672099A (en) Compositions and methods for wound healing
CA2584457A1 (en) Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
AU3934000A (en) Inhibitors of endothelin-1 synthesis
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ZA9711468B (en) New use of comt inhibitors
DE59905513D1 (de) Antisense-oligonukleotid zur hemmung der expression des adhäsionsmoleküls very late antigen 4 (vla-4) in menschlichen zellen
CA2330545A1 (en) Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: GROSSE, SCHUMACHER, KNAUER, VON HIRSCHHAUSEN, 8033